Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 7, 2014, Pages 1041-1048

  Hutterer, Georg C ^a   Stoeckigt, Caroline ^a   Stojakovic, Tatjana ^a   Jesche, Johanna ^a   Eberhard, Katharina ^a   Pummer, Karl ^a   Zigeuner, Richard ^a   Pichler, Martin ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Prognosis; Renal cell carcinoma; Validation study

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CELL RATIO; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISTANT METASTASIS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TUMOR NECROSIS; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TUMOR; LYMPHOCYTE; LYMPHOCYTE COUNT; MONOCYTE; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84924339462     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.04.001     Document Type: Article

References (29)

1. Ljungberg B., Campbell S.C., Choi H.Y., et al. The epidemiology of renal cell carcinoma. Eur Urol 2011, 60:615-621.
2. Pichler M., Hutterer G.C., Chromecki T.F., et al. Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5- and 10-year metastasis-free survival. Int Urol Nephrol 2012, 44:997-1004.
3. Sun M., Thuret R., Abdollah F., et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011, 59:135-141.
4. Meskawi M., Sun M., Trinh Q.D., et al. A review of integrated staging systems for renal cell carcinoma. Eur Urol 2012, 62:303-314.
5. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649-1657.
6. Kattan M.W., Reuter V., Motzer R.J., Katz J., Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63-67.
7. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671.
8. Crispen P.L., Boorjian S.A., Lohse C.M., Leibovich B.C., Kwon E.D. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008, 113:450-460.
9. Roxburgh C.S., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6:149-163.
10. Pichler M., Hutterer G.C., Stoeckigt C., et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013, 108:901-907.
11. Stotz M., Pichler M., Absenger G., et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer 2014, 110:435-440.
12. Szkandera J., Gerger A., Liegl-Atzwanger B., et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2013, 10.1002/ijc.28677.
13. Porrata L.F., Ristow K., Colgan J.P., et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin[U+05F3]s lymphoma. Haematologica 2012, 97:262-269.
14. Steidl C., Lee T., Shah S.P., et al. Tumor-associated macrophages and survival in classic Hodgkin[U+05F3]s lymphoma. N Engl J Med 2010, 362:875-885.
15. Novara G., Ficarra V., Antonelli A., et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?. Eur Urol 2010, 58:588-595.
16. Pichler M., Hutterer G.C., Chromecki T.F., et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol 2011, 186:1773-1777.
17. Absenger G., Szkandera J., Pichler M., et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013, 109:395-400.
18. Vickers A.J., Elkin E.B. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006, 26:565-574.
19. Al-Ali B.M., Ress A.L., Gerger A., Pichler M. MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2012, 32:3727-3732. [review].
20. Ficarra V., Brunelli M., Cheng L., et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 2010, 58:655-668.
21. Sun M., Shariat S.F., Cheng C., et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60:644-661.
22. Jagdev S.P., Gregory W., Vasudev N.S., et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010, 103:1649-1656.
23. Kondo T., Ito F., Nakazawa H., Horita S., Osaka Y., Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004, 171:2171-2175.
24. + memory T cells in renal cell carcinoma. Br J Cancer 2011, 105:1191-1196.
25. Liotta F., Gacci M., Frosali F., et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2011, 107:1500-1506.
26. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
27. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006, 25:315-322.
28. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
29. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.